Ahmad A, Zaheer M, Balis FJ (2024). Baricitinib. In StatPearls. https://www.ncbi.nlm.nih.gov/pubmed/34283430

Ali E, Owais R, Sheikh A, Shaikh A (2022) Olumniant (Baricitinib) oral tablets: an insight into FDA-approved systemic treatment for alopecia areata. Ann Med Surg (Lond) 80:104157. https://doi.org/10.1016/j.amsu.2022.104157

Article  PubMed  Google Scholar 

Anderson, L. A. (2023). Which JAK inhibitors are approved in the U.S? https://www.drugs.com/medical-answers/jak-inhibitors-approved-3575793/.

Angelini J, Talotta R, Roncato R, Fornasier G, Barbiero G, Dal Cin L, Brancati S, Scaglione F (2020) JAK-Inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future. Biomolecules. https://doi.org/10.3390/biom10071002

Article  PubMed  PubMed Central  Google Scholar 

FDA Approves JAK Inhibitor Deuruxolitinib for Alopecia Areata - Medscape. (2024). Medscape - https://www.medscape.com/viewarticle/fda-approves-jak-inhibitor-deuruxolitinib-alopecia-areata-2024a1000dsz?form=fpf.

Baker KF, Isaacs JD (2018) Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis 77(2):175–187. https://doi.org/10.1136/annrheumdis-2017-211555

Article  CAS  PubMed  Google Scholar 

Benucci M, Damiani A, Infantino M, Manfredi M, Lari B, Grossi V, Gobbi FL, Sarzi-Puttini P (2022) Cardiovascular safety, cancer and Jak-inhibitors: differences to be highlighted. Pharmacol Res 183:106359. https://doi.org/10.1016/j.phrs.2022.106359

Article  CAS  PubMed  Google Scholar 

Clark JD, Flanagan ME, Telliez JB (2014) Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem 57(12):5023–5038. https://doi.org/10.1021/jm401490p

Article  CAS  PubMed  Google Scholar 

Costanzo G, Firinu D, Losa F, Deidda M, Barca MP, Del Giacco S (2020) Baricitinib exposure during pregnancy in rheumatoid arthritis. Ther Adv Musculoskelet Dis 12:1759720X19899296. https://pubmed.ncbi.nlm.nih.gov/32071617/

Article  PubMed  PubMed Central  Google Scholar 

COVID-19 update: baricitinib (Olumiant) FDA-approved for treatment of COVID-19. (2022). Med Lett Drugs Ther, 64(1652), e2-e3. https://www.ncbi.nlm.nih.gov/pubmed/35657369

Elovic A, Pourmand A (2020) Lexicomp app review. J Digit Imaging 33(1):17–20. https://doi.org/10.1007/s10278-019-00219-x

Article  PubMed  Google Scholar 

Haq, M., & Adnan, G. (2024). Ruxolitinib. In StatPearls. https://www.ncbi.nlm.nih.gov/pubmed/34033362

Iznardo H, Roe E, Serra-Baldrich E, Puig L (2023) Efficacy and safety of JAK1 inhibitor abrocitinib in atopic dermatitis. Pharmaceutics. https://doi.org/10.3390/pharmaceutics15020385

Article  PubMed  PubMed Central  Google Scholar 

Jinesh S (2015) Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs. Inflammopharmacology 23(2–3):71–77

Article  CAS  PubMed  Google Scholar 

Kiladjian JJ, Vannucchi AM, Gerds AT, Gupta V, Verstovsek S, Egyed M, Platzbecker U, Mayer J, Grosicki S, Illes A, Wozny T, Oh ST, McLornan D, Kirgner I, Yoon SS, Harrison CN, Klencke B, Huang M, Kawashima J, Mesa R (2023) Momelotinib in myelofibrosis patients with thrombocytopenia: post hoc analysis from three randomized phase 3 trials. Hemasphere 7(11):e963. https://doi.org/10.1097/HS9.0000000000000963

Article  CAS  PubMed  PubMed Central  Google Scholar 

King B, Senna MM, Mesinkovska NA, Lynde C, Zirwas M, Maari C, Prajapati VH, Sapra S, Brzewski P, Osman L, Hanna S, Wiseman MC, Hamilton C, Cassella J (2024) Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. https://doi.org/10.1016/j.jaad.2024.06.097

Article  PubMed  Google Scholar 

Kramer A, Prinz C, Fichtner F, Fischer AL, Thieme V, Grundeis F, Spagl M, Seeber C, Piechotta V, Metzendorf MI, Golinski M, Moerer O, Stephani C, Mikolajewska A, Kluge S, Stegemann M, Laudi S, Skoetz N (2022) Janus kinase inhibitors for the treatment of COVID-19. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD015209

Article  PubMed  PubMed Central  Google Scholar 

Kubo S, Nakayamada S, Tanaka Y (2023) JAK inhibitors for rheumatoid arthritis. Expert Opin Investig Drugs 32(4):333–344. https://doi.org/10.1080/13543784.2023.2199919

Article  CAS  PubMed  Google Scholar 

LexiComp. UpToDate Lexidrug. UpToDate Inc. https://online.lexi.com. Accessed 28 Apr 2024

Luo Y, Alexander M, Gadina M, O’Shea JJ, Meylan F, Schwartz DM (2021) JAK-STAT signaling in human disease: from genetic syndromes to clinical inhibition. J Allergy Clin Immunol 148(4):911–925. https://doi.org/10.1016/j.jaci.2021.08.004

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lv Y, Qi J, Babon JJ, Cao L, Fan G, Lang J, Zhang J, Mi P, Kobe B, Wang F (2024) The JAK-STAT pathway: from structural biology to cytokine engineering. Signal Transduct Target Ther 9(1):221. https://doi.org/10.1038/s41392-024-01934-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mascarenhas J (2022) Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia. Expert Rev Hematol 15(8):671–684. https://doi.org/10.1080/17474086.2022.2112565

Article  CAS  PubMed  Google Scholar 

Padda IS, Bhatt R, Parmar M (2024). Tofacitinib. In StatPearls. https://www.ncbi.nlm.nih.gov/pubmed/34283514

Padda IS, Bhatt R, Patel P, Parmar M (2024). Upadacitinib. In StatPearls. https://www.ncbi.nlm.nih.gov/pubmed/34283454

Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DYM, Forman SB, Venturanza ME, Sun K, Kuligowski ME, Simpson EL (2021) Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol 85(4):863–872. https://pubmed.ncbi.nlm.nih.gov/33957195/

Article  CAS  PubMed  Google Scholar 

Perche PO, Cook MK, Feldman SR (2023) Abrocitinib: a new FDA-approved drug for moderate-to-severe atopic dermatitis. Ann Pharmacother 57(1):86–98. https://doi.org/10.1177/10600280221096713

Article  CAS  PubMed  Google Scholar 

Sarapultsev A, Gusev E, Komelkova M, Utepova I, Luo S, Hu D (2023) JAK-STAT signaling in inflammation and stress-related diseases: implications for therapeutic interventions. Mol Biomed 4(1):40. https://doi.org/10.1186/s43556-023-00151-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Talpaz M, Kiladjian JJ (2021) Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. Leukemia 35(1):1–17. https://doi.org/10.1038/s41375-020-0954-2

Article  CAS  PubMed  Google Scholar 

Tanaka Y, Luo Y, O’Shea JJ, Nakayamada S (2022) Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol 18(3):133–145. https://doi.org/10.1038/s41584-021-00726-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

The Lancet R (2024) JAK inhibitors-friend or foe? Lancet Rheumatol 6(3):e129. https://doi.org/10.1016/S2665-9913(24)00033-X

Article  Google Scholar 

Tokareva K, Reid P, Yang V, Liew D, Peterson AC, Baraff A, Giles J, Singh N (2023) JAK inhibitors and black box warnings: what is the future for JAK inhibitors? Expert Rev Clin Immunol 19(11):1385–1397. https://doi.org/10.1080/1744666X.2023.2249237

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tyczynska KM, Augustyniak-Bartosik H, Swierkot J (2023) Rheumatoid arthritis—medication dosage in chronic kidney disease. Reumatologia 61(6):481–491. https://doi.org/10.5114/reum/177005

Article  PubMed  Google Scholar 

Venugopal S, Mascarenhas J (2022) The odyssey of pacritinib in myelofibrosis. Blood Adv 6(16):4905–4913. https://doi.org/10.1182/bloodadvances.2022007524

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xin P, Xu X, Deng C, Liu S, Wang Y, Zhou X, Ma H, Wei D, Sun S (2020) The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol 80:106210. https://doi.org/10.1016/j.intimp.2020.106210